Skip to main content

Table 2 Characteristics of neutropenic vs non-neutropenic patients after propensity score matching

From: Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status

 

Non-neutropenic (n = 148)

Neutropenic (n = 148)

p value

Age (median [IQR])

55.55 (15.85)

55.75 (14.12)

0.91

Female (%)

54 (36.5)

49 ( 33.1)

0.63

SOFA (median [IQR])

8.00 [5.00, 10.00]

10.00 [7.00, 12.00]

< 0.001

Hematopoietic cell transplant (HCT)

0.07

 No (HCT)

107 (72.3)

97 (65.5)

 

 Autologous HCT

12 (8.1)

25 (16.9)

 

 Allogeneic HCT

29 (19.6)

26 ( 17.6)

 

Immune defect (ID)

0.94

 Acute leukemia

66 (44.6)

62 (41.9)

 

 Chronic leukemia

2 (1.4)

6 (4.1)

 

 Hodgkin disease

7 (4.7)

5 (3.4)

 

 Drug-induced immunosuppression

1 (0.7)

1 (0.7)

 

 Myeloma

13 (8.8)

13 (8.8)

 

 Non-Hodgkin lymphoma

31 (20.9)

32 (21.6)

 

 Other

10 ( 6.8)

11 (7.4)

 

 Solid tumor

16 (10.8)

17 (11.5)

 

 Systemic

2 ( 1.4)

1 (0.7)

 

 Kidney comorbidity

13 ( 8.8)

9 (6.1)

0.51

Respiratory support

  

0.73

High-flow nasal oxygen

28 (18.9)

24 (16.2)

 

Non-invasive ventilation

13 ( 8.8)

16 (10.8)

 

O2

78 (52.7)

84 (56.8)

 

Mechanical ventilation

29 (19.6)

24 (16.2)

 

Vasopressors

115 (77.7)

103 (69.6)

0.15

Renal replacement therapy

42 (28.4)

39 (26.4)

0.79

Acute respiratory failure diagnosis

0.82

 Bacterial

69 (46.6)

73 (49.3)

 

 Fungal

15 (10.1)

16 (10.8)

 

 Other

49 (33.1)

44 (29.7)

 

 Pneumocystis

1 ( 0.7)

3 (2.0)

 

 Unknown

14 ( 9.5)

12 (8.1)

 

 No BAL use

77 (52.0)

95 (64.2)

0.05

 Hospital mortality

68 (45.9)

77 (52.0)

0.35

  1. SOFA Sequential Organ Failure Assessment score, BAL bronchoalveolar lavage